← Back to headlines
AbbVie Submits Application for Subcutaneous Skyrizi to FDA
AbbVie has submitted an application to the FDA for a subcutaneous formulation of its drug Skyrizi, seeking approval for the new delivery method.
27 Apr, 16:09 — 27 Apr, 16:09
Sources
Showing 1 of 1 sources
